Dab2 is pivotal for endothelial cell migration by mediating VEGF expression in cancer cells

Experimental Cell Research

Volumn 318, Issue 5, 2012, Pages 550-557

  Cheong, Seong Moon ^a   Choi, Hyemin ^a   Hong, Bok Sil ^a   Gho, Yong Song ^a   Han, Jin Kwan ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

Angiogenesis; Cancer; Dab2; HUVEC; TGF beta; VEGF

Indexed keywords

DISABLED 2 PROTEIN; FIBROBLAST GROWTH FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL MIGRATION; COLON CANCER; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84857056951     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.01.013     Document Type: Article

References (39)

1. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
2. Breier G., Albrecht U., Sterrer S., Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992, 114:521-532.
3. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
4. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
5. Peters K.G., De Vries C., Williams L.T. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8915-8919.
6. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
7. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
8. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
9. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
10. Pardali E., Goumans M.J., ten Dijke P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 2010, 20:556-567.
11. Larsson J., Goumans M.J., Sjostrand L.J., van Rooijen M.A., Ward D., Leveen P., Xu X., ten Dijke P., Mummery C.L., Karlsson S. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J. 2001, 20:1663-1673.
12. Dickson M.C., Martin J.S., Cousins F.M., Kulkarni A.B., Karlsson S., Akhurst R.J. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995, 121:1845-1854.
13. Oshima M., Oshima H., Taketo M.M. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. 1996, 179:297-302.
14. Sanchez-Elsner T., Botella L.M., Velasco B., Corbi A., Attisano L., Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 2001, 276:38527-38535.
15. Pepper M.S., Vassalli J.D., Orci L., Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp. Cell Res. 1993, 204:356-363.
16. Nagineni C.N., Samuel W., Nagineni S., Pardhasaradhi K., Wiggert B., Detrick B., Hooks J.J. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J. Cell. Physiol. 2003, 197:453-462.
17. Kitamura S., Maeshima Y., Sugaya T., Sugiyama H., Yamasaki Y., Makino H. Transforming growth factor-beta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells. Nephron Exp. Nephrol. 2003, 95:e79-e86.
18. Renner U., Lohrer P., Schaaf L., Feirer M., Schmitt K., Onofri C., Arzt E., Stalla G.K. Transforming growth factor-beta stimulates vascular endothelial growth factor production by folliculostellate pituitary cells. Endocrinology 2002, 143:3759-3765.
19. Gary Lee Y.C., Melkerneker D., Thompson P.J., Light R.W., Lane K.B. Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. Am. J. RespirCrit. Care Med. 2002, 165:88-94.
20. Benckert C., Jonas S., Cramer T., Von Marschall Z., Schafer G., Peters M., Wagner K., Radke C., Wiedenmann B., Neuhaus P., Hocker M., Rosewicz S. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003, 63:1083-1092.
21. Enholm B., Paavonen K., Ristimaki A., Kumar V., Gunji Y., Klefstrom J., Kivinen L., Laiho M., Olofsson B., Joukov V., Eriksson U., Alitalo K. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997, 14:2475-2483.
22. Mishra S.K., Keyel P.A., Hawryluk M.J., Agostinelli N.R., Watkins S.C., Traub L.M. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. EMBO J. 2002, 21:4915-4926.
23. Xu X.X., Yi T., Tang B., Lambeth J.D. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene 1998, 16:1561-1569.
24. Zhou J., Hsieh J.T. The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J. Biol. Chem. 2001, 276:27793-27798.
25. Yang D.H., Smith E.R., Roland I.H., Sheng Z., He J., Martin W.D., Hamilton T.C., Lambeth J.D., Xu X.X. Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis. Dev. Biol. 2002, 251:27-44.
26. Morris S.M., Tallquist M.D., Rock C.O., Cooper J.A. Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. EMBO J. 2002, 21:1555-1564.
27. Mok S.C., Chan W.Y., Wong K.K., Cheung K.K., Lau C.C., Ng S.W., Baldini A., Colitti C.V., Rock C.O., Berkowitz R.S. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998, 16:2381-2387.
28. Kleeff J., Huang Y., Mok S.C., Zimmermann A., Friess H., Buchler M.W. Down-regulation of DOC-2 in colorectal cancer points to its role as a tumor suppressor in this malignancy. Dis. Colon Rectum 2002, 45:1242-1248.
29. Karam J.A., Shariat S.F., Huang H.Y., Pong R.C., Ashfaq R., Shapiro E., Lotan Y., Sagalowsky A.I., Wu X.R., Hsieh J.T. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin. Cancer Res. 2007, 13:4400-4406.
30. Tong J.H., Ng D.C., Chau S.L., So K.K., Leung P.P., Lee T.L., Lung R.W., Chan M.W., Chan A.W., Lo K.W., To K.F. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010, 10:253.
31. Hocevar B.A., Smine A., Xu X.X., Howe P.H. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J. 2001, 20:2789-2801.
32. Song H.D., Sun X.J., Deng M., Zhang G.W., Zhou Y., Wu X.Y., Sheng Y., Chen Y., Ruan Z., Jiang C.L., Fan H.Y., Zon L.I., Kanki J.P., Liu T.X., Look A.T., Chen Z. Hematopoietic gene expression profile in zebrafish kidney marrow. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16240-16245.
33. Cheong S.M., Choi S.C., Han J.K. Xenopus Dab2 is required for embryonic angiogenesis. BMC Dev. Biol. 2006, 6:63.
34. Orlandini M., Nucciotti S., Galvagni F., Bardelli M., Rocchigiani M., Petraglia F., Oliviero S. Morphogenesis of human endothelial cells is inhibited by DAB2 via Src. FEBS Lett. 2008, 582:2542-2548.
35. Kim C.W., Lee H.M., Lee T.H., Kang C., Kleinman H.K., Gho Y.S. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res. 2002, 62:6312-6317.
36. Wang Z., Tseng C.P., Pong R.C., Chen H., McConnell J.D., Navone N., Hsieh J.T. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J. Biol. Chem. 2002, 277:12622-12631.
37. Pardali K., Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim. Biophys. Acta 2007, 1775:21-62.
38. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
39. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6:273-286.